HnRNPK-targeted lentivirus shRNA and application thereof
Through the lentiviral shRNA targeting hnRNPK interferes with hnRNPK gene expression, the problem of poor sensitivity of esophageal cancer to radiotherapy is solved, significantly reduces the invasion of esophageal cancer cells and wound healing ability, enhances the sensitivity of esophageal cancer cells to radiation, and provides new treatment strategies.
Patent Information
- Application Number
- CN202411184222.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-27
- Publication Date
- 2024-11-15
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Patients with esophageal cancer have poor sensitivity to radiotherapy, resulting in uneven radiotherapy effects and high recurrence rates, and lack of effective strategies to enhance radiosensitivity of esophageal cancer.
A lentiviral shRNA targeting hnRNPK was designed to reduce the proliferation, invasion and wound healing ability of esophageal cancer cells by interfering with hnRNPK gene expression and enhance the sensitivity of esophageal cancer cells to radiation.
Through the lentiviral shRNA targeting hnRNPK, it significantly reduces the invasion of esophageal cancer cells and wound healing ability, enhances the sensitivity of esophageal cancer cells to radiation, provides a new gene target and drug, and has high clinical application value.
Smart Images

Figure CN118956873A_ABST
